Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.
Humanigen and EVERSANA Announce Partnership to Support Launch and Commercialization of Lenzilumab for Treatment of COVID-19
Biologics License Application (BLA), Business, Coronavirus Disease 2019 (COVID-19), Cytokine Storm, Emergency Use Authorization (EUA), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Hospitalized COVID-19 Patients, Partnerships, Product LaunchesHumanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.
Veru’s Compound Shows Promise as Antiviral/Anti-Inflammatory Therapeutic for Covid-19
Anti-Inflammatory, Antigens, Antivirals, Cancer, Cell Signaling, Clinical Studies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Cytokine Storm, Prostate Cancer, R&D, Therapeutics, University of TennesseeVeru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.